Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Food and Drug Administration drug insert for Campath (alemtuzumab)
Genetics of multiple sclerosis: swimming in an ocean of data.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Vitamin D intake and incidence of multiple sclerosis.
Mitoxantrone for multiple sclerosis.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
Study hints of rituximab MS benefit
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Fingolimod is a potential novel therapy for multiple sclerosis.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Pharmacokinetic properties and metabolism of idebenone.
Glatiramer acetate treatment negatively regulates type I interferon signaling.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.

Pages